Cancer Stem Cells in Acute Leukemia
Active, not recruiting
- Conditions
- Acute Leukemia
- Registration Number
- NCT03735797
- Lead Sponsor
- Sanford Health
- Brief Summary
Descriptive study of acute leukemia patients. Bone marrow aspirate or peripheral blood samples will be analyzed by next-generation sequencing for novel gene signatures and variations in transcriptional and epigenetic regulatory elements such as ARID5B and SALL4 variants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Newly diagnosed or relapsed acute leukemia (AML or ALL)
- Plan to undergo diagnostic bone marrow aspirate or peripheral blood if clinically indicated (i.e. WBC>50,000 and bone marrow contraindicated)
- Age 1 month to 30 years
- Understand and provide informed consent (subject if>18, legal guardian if<18)
Exclusion Criteria
- Age 0 to 4 weeks
- Treatment related leukemia or leukemia secondary to MDS
- Situations that would limit compliance with study requirements or ability to willingly give consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ARID5B polymorphism/mutation status 5 years Correlation of our experimentally validated Arid5b dependent transcriptional signature with primary patient samples measured by patient ARID5B expression and polymorphisms.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sanford Health
🇺🇸Sioux Falls, South Dakota, United States